Core Viewpoint - Heng Rui Medicine (01276) announced that its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of SHR-7782 injection, which will soon commence clinical trials [1] Group 1: Product Development - SHR-7782 injection is a self-developed therapeutic biological product that specifically binds to tumor cell surface antigens to kill tumor cells, intended for the treatment of advanced solid tumors [1] - Currently, there are no similar drugs approved for marketing domestically or internationally [1] Group 2: Financial Investment - The cumulative research and development investment for the SHR-7782 injection project has reached approximately 48.2 million yuan [1]

Group 1 - The core point of the article is that Edding Biotechnology (01061.HK) has received acceptance for its biopharmaceutical license application for the anti-VEGF eye injection product HLX04-O, intended for the treatment of wet AMD, from the National Medical Products Administration (NMPA) in China [1] - HLX04-O is developed based on the independently researched Hanbeitai (Bevacizumab injection) by the company, optimized for ophthalmic use in terms of formulation, specifications, and production processes while maintaining the same active ingredient [1] - As of the announcement date, there are no approved Bevacizumab products for the treatment of wet AMD in China, with projected sales for drugs targeting wet AMD in China estimated at approximately RMB 4.9 billion for 2024 according to the latest data from IQVIA CHPA [1]

Group 1 - The core point of the news is that 前沿生物 (Frontier Biotech) is currently experiencing a decline in stock price, with a closing price of 20.07 yuan and a drop of 7.55% [1] - Frontier Biotech was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 28, 2020, with an initial public offering (IPO) of 89.96 million shares, accounting for 25.01% of the total shares post-issue, at a price of 20.50 yuan per share [1] - The highest stock price recorded since the IPO was 35.53 yuan, indicating that the stock is currently in a state of decline [1] Group 2 - The total amount raised from the IPO was 184.418 million yuan, with a net amount of 171.729 million yuan after expenses [1] - The company planned to use the raised funds for various projects, including the clinical development of an HIV fusion inhibitor, a combined therapy, a new transdermal analgesic patch, marketing network construction, and to supplement working capital [1] - The total issuance costs for the IPO (excluding VAT) were 12.689 million yuan, with underwriting and sponsorship fees amounting to 11.613 million yuan [1] Group 3 - On September 22, 2022, Frontier Biotech announced a specific issuance of 14,818,653 shares at a price of 13.51 yuan per share, raising a total of approximately 200.200 million yuan [2] - After deducting issuance costs of approximately 4.533 million yuan, the net amount raised was about 195.667 million yuan [2] - The total fundraising from both the IPO and the subsequent issuance amounts to approximately 2.044 billion yuan [3]

值得注意的是，和誉近日宣布，其研发的新型PRMT5*MTA抑制剂ABSK131，已在针对MTAP缺失的晚 期/转移性实体瘤患者的1期临床试验中完成首例患者给药。据悉，2024年12月，ABSK131获得美国食品 药品监督管理局的IND批准。2025年3月，ABSK131获中国国家药品监督管理局药品审评中心的IND批 准。 消息面上，和誉发布业绩，上半年收入6.12亿元人民币，同比增加23.1%；期内经调整利润3.36亿元， 同比增加56.03%；净利润3.28亿元，同比增加58.84%。公告称，收入主要为来自默克的授权收入。此 外，公司购回股份以提振市场信心及提升股东价值。截至2025年6月30日止6个月，公司共购回954.5万 股股份，累计金额7530万港元。于2024年，亦合计购回2259.4万股股份，累计金额6870万港元。 和誉-B(02256)绩后涨近7%，截至发稿，涨4.02%，报10.87港元，成交额1.46亿港元。 ...

Core Viewpoint - Hunan Maijizhi Biotechnology Co., Ltd. (referred to as "Maijizhi") has submitted an application for listing on the Hong Kong Stock Exchange, with CICC as the exclusive sponsor. The company has been experiencing continuous losses but has seen its post-investment valuation increase nearly 45 times over the past eight years [1][2][9]. Company Overview - Established in 2016, Maijizhi is a clinical-stage biopharmaceutical company focused on addressing unmet medical needs in allergic diseases, autoimmune diseases, and other inflammatory and immune diseases. The company currently has no products on the market, with its core product MG-K10 being a long-acting anti-IL-4Rα antibody with "best-in-class" potential [5][6]. Product Pipeline - MG-K10 targets atopic dermatitis (AD), a chronic inflammatory skin disease with a significant global burden, affecting at least 230 million people. In China, the prevalence of AD has increased by 25.65% from 1990 to 2019, with approximately 36.09 million patients currently, including about 9.63 million with moderate to severe cases [5][6]. - In addition to MG-K10, Maijizhi has two other self-developed products in clinical stages: MG-014, targeting asthma and COPD, and MG-013, an anti-MASP-2 monoclonal antibody aimed at rare and inflammatory diseases [6][7]. Financial Performance - For the first three months of 2023, 2024, and 2025, Maijizhi reported revenues of 8.72 million, 24,000, and 0, respectively, with corresponding net losses of 253 million, 178 million, and 27.3 million. The company incurred significant R&D expenses of 166 million and 150 million in 2023 and 2024, leading to a total adjusted net loss of approximately 307 million over these two years [7][8]. - In Q1 2025, the company recorded no revenue and continued to incur losses with R&D expenses of 24.3 million [8]. Valuation Growth - The company's valuation has seen substantial growth over the years, starting from 58 million in early 2017 to 2.64 billion in May 2025, reflecting a nearly 45-fold increase [9][10]. IPO Fund Utilization - The funds raised from the IPO will be used for ongoing and planned clinical trials of the core product MG-K10, as well as for MG-014 and MG-013, along with other preclinical and discovery-stage assets [11].

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has issued supplementary material requirements for nine companies, including Hemei Pharmaceutical, which is seeking to list on the Hong Kong Stock Exchange. The CSRC is requesting detailed explanations regarding the company's previous A-share listing guidance and its future plans for A-share listing [1][2]. Group 1 - The CSRC has requested Hemei Pharmaceutical to clarify its previous A-share listing guidance and whether it plans to continue with the A-share listing, including any significant impacts on the current listing process [1][2]. - Hemei Pharmaceutical was established in 2002 and is an innovative biopharmaceutical company focused on discovering and developing small molecule drugs for autoimmune diseases and tumors, maintaining a leading position in the development of treatments for psoriasis, Behçet's disease, and inflammatory bowel disease [2]. - As of May 21, 2025, Hemei Pharmaceutical has developed seven small molecule drug candidates targeting high unmet needs in autoimmune and tumor diseases, with four candidates in Phase II, III clinical trials, or NDA stages for twelve indications [2]. Group 2 - Hemei Pharmaceutical's core product, Mufemilast, is a novel small molecule phosphodiesterase 4B (PDE4B) protein expression blocker and PDE4 inhibitor, showing potential for treating a wide range of autoimmune diseases. According to Frost & Sullivan, Mufemilast may be a first-in-class drug with dual mechanisms of action [2].

百奥泰公告，近日收到国家药品监督管理局核准签发的关于公司在研药品重组抗VEGF人源化单克隆抗 体注射液(BAT5906)新增视网膜中央静脉阻塞所致黄斑水肿(CRVO-ME)和病理性近视的脉络膜新生血管 (pmCNV)的《药物临床试验批准通知书》。BAT5906是百奥泰自主研发生产的重组人源化单克隆抗体创 新药物，为IgG1型全长抗体，分子量为149KDa，能与人VEGF-A165进行特异性结合，抑制新生血管生 成。在体外血管生成模型上，BAT5906能够阻断VEGF与其相应的受体结合，抑制内皮细胞的增殖和新 生血管形成。在动物实验中，BAT5906的血清半衰期比结构为Fab片段的雷珠单抗更长，可能会支持临 床中更长的注射周期。在用药安全性上，不会触发抗体依赖的细胞介导的细胞毒性作用(ADCC)，因而 全身不良反应小，临床应用可能更安全。 ...

瑞银重申康方生物买入评级 目标价一举升至197.5港元 金十数据8月1日讯，瑞银发表研究报告指，康方生物(09926.HK)核心产品AK112（ivonescimab）在非小 细胞肺癌（NSCLC）外的适应症展现巨大潜力，除NSCLC的6项适应症外，公司另启动6项三期临床试 验，覆盖胆管癌、三阴性乳腺癌、胰腺癌等一线治疗领域，适应症广度居同类药物之首。瑞银指，该药 物自今年1月纳入国家医保目录后销售快速增长，5月获批NSCLC一线治疗新适应症，有望通过2025年 医保谈判进一步贡献增量收入，将AK112在中国及全球销售高峰值上调至12亿及146亿美元，重申买入 评级，并将目标价从112.1港元大幅上调至197.5港元。 ...

Core Viewpoint - Hunan Maijiz Biological Technology Co., Ltd. has submitted an application for an IPO on the Hong Kong Stock Exchange, with CICC as the sole sponsor [1] Company Overview - Maijiz Biological was established in 2016 and is a clinical-stage biopharmaceutical company focused on unmet medical needs in allergic diseases, autoimmune diseases, and other inflammatory and immune diseases [3] - The company currently has no products on the market, with its core product MG-K10 being a long-acting anti-IL-4Rα antibody, which is considered to have "best-in-class" potential [3] Financial Performance - The company has reported continuous losses, with a total adjusted net loss of approximately 307 million yuan over the past two years [5] - Revenue for the first three months of 2023, 2024, and 2025 was 872,200 yuan, 24,000 yuan, and 0 yuan respectively, with corresponding net losses of 253 million yuan, 178 million yuan, and 27.3 million yuan [4] Product Pipeline - In addition to MG-K10, Maijiz Biological has two other self-developed pipelines that have entered clinical stages: MG-014 targeting TSLP for asthma and COPD, and MG-013 targeting MASP-2 for rare and inflammatory diseases [4] - The company has several other preclinical candidates, including MG-012, MG-015, MG-018, MG-208, and MG-242, which are in development [4] Valuation and Funding - The company has undergone multiple rounds of financing, raising over 700 million yuan, with a post-money valuation growth of nearly 45 times over eight years [7] - The valuation increased from 58 million yuan in early 2017 to 2.64 billion yuan in May 2025 [10] Shareholding Structure - The controlling shareholder, Zhang Chenghai, holds approximately 42.65% of the company, while other significant shareholders include Kangzhe Pharmaceutical and Hunan Guochuang [10] Use of IPO Proceeds - The funds raised from the IPO will be used for ongoing and planned clinical trials of the core product MG-K10, as well as for MG-014, MG-013, and other preclinical and discovery-stage assets [10]

Core Insights - Ipsen reported strong financial results for H1 2025, with total sales reaching €1,819.8 million, a 9.7% increase compared to H1 2024, and 11.4% growth at constant exchange rates (CER) [2][3] - The company achieved a core operating income of €655.8 million, reflecting a 21.9% increase, and a core operating margin of 36.0%, up by 3.6 percentage points [2][3] - Ipsen upgraded its full-year 2025 financial guidance, expecting total sales growth greater than 7.0% at CER, and a core operating margin exceeding 32.0% [3][4] Financial Performance - Total sales for H1 2025 were €1,819.8 million, compared to €1,659.3 million in H1 2024, marking a 9.7% increase [2] - Core operating income rose to €655.8 million from €538.0 million, a growth of 21.9% [2] - Core consolidated net profit increased by 27.3% to €508.3 million, with core earnings per share rising to €6.07 from €4.78 [2] - IFRS operating income was €451.6 million, up 42.1%, with an IFRS operating margin of 24.8%, an increase of 5.7 percentage points [2] Therapeutic Areas Performance - Sales growth was driven by three therapeutic areas: 95.7% in Rare Disease, 9.7% in Neuroscience, and 6.4% in Oncology [3] - The rare liver disease franchise showed particularly strong momentum, contributing significantly to overall sales growth [3] Pipeline and Regulatory Updates - Ipsen received European Commission approval for Cabometyx in advanced neuroendocrine tumors on July 23, 2025, marking the sixth indication for the drug [3][6] - The company is anticipating pivotal study results for fidrisertib in fibrodysplasia ossificans progressiva (FOP) and proof-of-concept data for LANT in aesthetics in the second half of 2025 [3][4] - Recent pipeline developments include the initiation of a Phase II study of LANT in cervical dystonia and the presentation of Iqirvo® data at a major liver congress [5][6] Future Outlook - The company expects a negative impact on Somatuline sales due to increased generic competition in the U.S. and Europe, but remains optimistic about overall growth [4][11] - Ipsen's strategy focuses on external innovation and a commitment to scientific excellence, positioning the company for continued positive impact in the biopharmaceutical sector [4]